
Taro Pharmaceutical Industries Ltd. TARO
Annual report 2022
added 07-25-2022
Taro Pharmaceutical Industries Ltd. Total Assets 2011-2026 | TARO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Taro Pharmaceutical Industries Ltd.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.18 B | 2.41 B | 2.34 B | 2.14 B | 2.43 B | 2.29 B | 2.19 B | 1.74 B | 1.28 B | 1.11 B | 856 M | 796 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.43 B | 796 M | 1.81 B |
Quarterly Total Assets Taro Pharmaceutical Industries Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 2.41 B | - | - | - | 2.34 B | - | - | - | 2.14 B | - | - | - | 2.43 B | - | - | - | 2.29 B | - | - | - | 2.19 B | - | - | - | 1.74 B | - | - | - | 1.28 B | - | - | - | 1.11 B | - | - | - | 856 M | 796 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.43 B | 796 M | 1.78 B |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | ||
|
AbbVie
ABBV
|
134 B | $ 209.63 | -0.71 % | $ 371 B | ||
|
Verastem
VSTM
|
246 M | $ 4.99 | -5.77 % | $ 346 M | ||
|
VistaGen Therapeutics
VTGN
|
84.3 M | $ 0.57 | -5.85 % | $ 17.6 M | ||
|
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | ||
|
Voyager Therapeutics
VYGR
|
252 M | $ 3.96 | -4.24 % | $ 232 M | ||
|
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
24.2 M | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
619 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - | ||
|
Avid Bioservices
CDMO
|
337 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
513 M | $ 12.36 | -11.46 % | $ 1.88 B | ||
|
Wave Life Sciences Ltd.
WVE
|
638 M | $ 6.39 | 3.06 % | $ 1.08 B | ||
|
Xenetic Biosciences
XBIO
|
8.36 M | $ 2.78 | -0.71 % | $ 4.73 M | ||
|
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B | ||
|
XBiotech
XBIT
|
150 M | $ 2.27 | -1.73 % | $ 69.2 M | ||
|
Xenon Pharmaceuticals
XENE
|
798 M | $ 54.44 | -1.96 % | $ 4.24 B | ||
|
Xeris Pharmaceuticals
XERS
|
384 M | $ 5.41 | -2.87 % | $ 868 M | ||
|
X4 Pharmaceuticals
XFOR
|
290 M | $ 4.07 | -5.57 % | $ 172 M | ||
|
Xencor
XNCR
|
875 M | $ 11.4 | -7.43 % | $ 846 M | ||
|
XOMA Corporation
XOMA
|
273 M | $ 29.93 | -1.97 % | $ 362 M | ||
|
22nd Century Group
XXII
|
27 M | $ 2.41 | -18.03 % | $ 444 K | ||
|
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
126 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
426 M | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
27.7 M | $ 1.06 | -2.75 % | $ 21.7 M | ||
|
Enochian Biosciences
ENOB
|
8.23 M | - | - | $ 40.5 M |